Last reviewed · How we verify
Fang Le Shu (Follitrope)
Fang Le Shu (Follitrope) is a Gonadotropin; recombinant FSH Small molecule drug developed by LG Chem. It is currently FDA-approved for Infertility in women undergoing assisted reproductive technology (ART), Anovulation and ovulatory dysfunction in women seeking fertility treatment.
Follitrope is a recombinant follicle-stimulating hormone (FSH) that stimulates the growth and maturation of ovarian follicles in women undergoing fertility treatment.
Follitrope is a recombinant follicle-stimulating hormone (FSH) that stimulates the growth and maturation of ovarian follicles in women undergoing fertility treatment. Used for Infertility in women undergoing assisted reproductive technology (ART), Anovulation and ovulatory dysfunction in women seeking fertility treatment.
At a glance
| Generic name | Fang Le Shu (Follitrope) |
|---|---|
| Sponsor | LG Chem |
| Drug class | Gonadotropin; recombinant FSH |
| Target | FSH receptor (FSHR) |
| Modality | Small molecule |
| Therapeutic area | Reproductive/Fertility |
| Phase | FDA-approved |
Mechanism of action
Follitrope binds to FSH receptors on granulosa cells of ovarian follicles, promoting follicular development and estrogen production. This hormone replacement therapy is used in assisted reproductive technology to induce controlled ovarian hyperstimulation, enabling the retrieval of multiple mature oocytes for in vitro fertilization or other fertility procedures.
Approved indications
- Infertility in women undergoing assisted reproductive technology (ART)
- Anovulation and ovulatory dysfunction in women seeking fertility treatment
Common side effects
- Ovarian hyperstimulation syndrome (OHSS)
- Headache
- Injection site reactions
- Abdominal pain/bloating
- Nausea
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fang Le Shu (Follitrope) CI brief — competitive landscape report
- Fang Le Shu (Follitrope) updates RSS · CI watch RSS
- LG Chem portfolio CI
Frequently asked questions about Fang Le Shu (Follitrope)
What is Fang Le Shu (Follitrope)?
How does Fang Le Shu (Follitrope) work?
What is Fang Le Shu (Follitrope) used for?
Who makes Fang Le Shu (Follitrope)?
What drug class is Fang Le Shu (Follitrope) in?
What development phase is Fang Le Shu (Follitrope) in?
What are the side effects of Fang Le Shu (Follitrope)?
What does Fang Le Shu (Follitrope) target?
Related
- Drug class: All Gonadotropin; recombinant FSH drugs
- Target: All drugs targeting FSH receptor (FSHR)
- Manufacturer: LG Chem — full pipeline
- Therapeutic area: All drugs in Reproductive/Fertility
- Indication: Drugs for Infertility in women undergoing assisted reproductive technology (ART)
- Indication: Drugs for Anovulation and ovulatory dysfunction in women seeking fertility treatment
- Compare: Fang Le Shu (Follitrope) vs similar drugs
- Pricing: Fang Le Shu (Follitrope) cost, discount & access